Showing 1071-1080 of 1477 results for "".
- Study Probes ODs’ Attitudes About Blue-Light Blocking Deviceshttps://modernod.com/news/study-probes-ods-attitudes-about-blue-light-blocking-devices/2476599/A recent study found that optometrists remain split on the impact of blue light from electronic devices, such as computer and phone screens, and the effectiveness of blue light-blocking devices, according to reporting by Patrick Campbell in MD Magazine, as
- Aldeyra Therapeutics to Present Phase 2b Dry Eye Disease Results at ARVOhttps://modernod.com/news/aldeyra-therapeutics-to-present-phase-2b-dry-eye-disease-results-at-arvo/2476456/Aldeyra Therapeutics announced that John Sheppard, MD, Professor of Ophthalmology at Eastern Virginia Medical School, will present results of the phase 2b clinical trial of topical reproxalap in dry eye disea
- Ivantis Announces 24-Month Results of Comparative MIGS Clinical Trialhttps://modernod.com/news/ivantis-announces-24-month-results-of-landmark-prospective-randomized-comparative-migs-clinical-trial/2476379/Ivantis, developer of the Hydrus Microstent, announced the 24-month results of the COMPARE study for minimally invasive glaucoma surgery (MIGS). Results from the study were presented by Thomas Samuelson, MD, President of the American Society of Cataract and Refracti
- Aldeyra Therapeutics Provides Update on Ophthalmic Programshttps://modernod.com/news/aldeyra-therapeutics-provides-update-on-ophthalmic-programs/2476256/Aldeyra Therapeutics updated progress on ophthalmic programs at a 2019 Research & Development Day in New York City. Presentations were given by members of the Aldeyra executive team along with Dean Eliott, MD, the Stelios Evangel
- Allegro Prepares To Take Lead Compound Risuteganib To Phase 3, Appoints New CEOhttps://modernod.com/news/allegro-prepares-to-take-lead-compound-risuteganib-to-phase-3-appoints-new-ceo/2479926/Allegro Ophthalmics announced that its board of directors has named Hampar Karageozian to the position of Executive Chairman and has appointed Vicken Karageozian, MD, to the position of President and Chief Executive O
- Vance Thompson Vision Announces New Clinic and LASIK and Cataract Center in Omahahttps://modernod.com/news/vance-thompson-vision-announces-new-clinic-and-lasik-and-cataract-center-in-omaha/2480189/Vance Thompson Vision is scheduled to open a new clinic in Omeha, Nebraska, in August and will include a focus on cataract surgery, minimally invasive glaucoma surgery, LASIK, and corneal surgery. Brandon Baartman, MD, is an accomplished refractive, cataract,
- Early Screening and Outdoor Activity Key to Tackling Childhood Myopia, Italian Study Findshttps://modernod.com/news/early-screening-and-outdoor-activity-key-to-tackling-childhood-myopia-italian-study-finds/2486939/Key Takeaways Early and regular eye screenings—starting around age 3—are critical for detecting and managing childhood myopia before it progresses
- Centre for Sight Launches 'Eye Health MOT' to Support Early Detection and Long-Term Vision Carehttps://modernod.com/news/centre-for-sight-launches-eye-health-mot-to-support-early-detection-and-long-term-vision-care/2485486/Centre for Sight has launched a new 'Eye Health MOT' service for people aged 40 and over, designed to offer a comprehensive, consultant-led assessment to detect early signs of eye disease before symptoms appear. According to C
- Inflammasome Therapeutics Reports Encouraging Early Results for K8 in Geographic Atrophyhttps://modernod.com/news/inflammasome-therapeutics-reports-encouraging-early-results-for-k8-in-geographic-atrophy/2484139/Inflammasome Therapeutics, which is developing a new class of inflammasome inhibitors known as Kamuvudines, announced promising early clinical data for its lead ophthalmic candidate K8. Delivered via a sustained-release intraocular implant, K8 reduced geograph
- Glaukos Receives EU MDR Certification for iStent infinite and iStent inject Whttps://modernod.com/news/glaukos-announces-european-union-mdr-certification-for-istent-infinite-and-istent-inject-w/2482868/Glaukos received European Union (EU) Medical Device Regulation (MDR) certification for iStent infinite, along with several of its other MIGS technologies, including iStent inject W. Glauko